偶氮二甲酸二甲酯 | 866731-50-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 偶氮二甲酸二甲酯
• 英文名称: dimethyl azodicarboxylate
• 英文别名: Azodicarbonsaeure-dimethylester；dimethyl diazenedicarboxylate；methyl azodicarboxylate；dimethyl azodiformate；trans-diazenedicarboxylic acid dimethyl ester；methyl (NE)-N-methoxycarbonyliminocarbamate
• CAS: 866731-50-2
• 化学式: C₄H₆N₂O₄
• 分子量: 146.103
• InChiKey: NCBFTYFOPLPRBX-AATRIKPKSA-N

物化性质

• 沸点：
  107-108 °C(Press: 31 Torr)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  偶氮二甲酸二甲酯 以49%的产率得到
  参考文献：
  名称：

  GIBBARD, A. C.;MOODY, CH. J.;REES, CH. W., J. CHEM. SOC. PERKIN TRANS., 1986, N 1, 145-149

  摘要：

  DOI：
• 作为产物：
  描述：

  叠氮基甲酸甲酯 生成 偶氮二甲酸二甲酯
  参考文献：
  名称：

  TELES, JOAQUIM HENRIQUE;MAIER, GUNTHER, CHEM. BER., 122,(1989) N, C. 745-748

  摘要：

  DOI：

文献信息

• 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
  申请人：Merck & Co., Inc.

  公开号：US04977146A1

  公开（公告）日：1990-12-11

  The present invention is directed to a specifically substituted tetrahydrofuran of the formula (I) ##STR1## wherein R.sup.4 is an alkylthio, alkylsulfinyl or alkylsulfonyl containing group, Y is an alkyl or substituted alkyl group, R.sup.6 is an alkyl or a substituted alkyl group and the substituents at positions 3, 4 or 5 are acyclic.

  本发明涉及具有以下结构的特定取代四氢呋喃化合物（I）##STR1##其中R.sup.4是含有烷基硫、烷基亚砜或烷基砜基团，Y是烷基或取代烷基团，R.sup.6是烷基或取代烷基团，而3、4或5位的取代基是非环状的。
• Amide compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04990511A1

  公开（公告）日：1991-02-05

  Amide compounds having glutamate receptor-inhibiting activity and having the formula: ##STR1## (wherein R.sub.1 and R.sub.2 each is hydrogen atom, an alkyl group or an acyl group, or ##STR2## is a cyclic amino group, m is an integer of 1 to 3, n is an integer of 0 to 4, x is an integer of 2 to 6 and y is an integer of 0 to 3) or salts thereof, are provided. The compounds are useful as a medicine for therapy or/and prevention of sequelae of cerebral apoplexy in warm-blooded animals.

  具有谷氨酸受体抑制活性的酰胺化合物，其化学式为：##STR1##（其中R.sub.1和R.sub.2分别为氢原子、烷基或酰基，或者##STR2##为环状氨基基团，m为1至3的整数，n为0至4的整数，x为2至6的整数，y为0至3的整数）或其盐。这些化合物可用作治疗或预防温血动物脑卒中后遗症的药物。
• 3-aryloxmethyl-cephalosporin derivatives, and their medical use
  申请人：Sankyo Company, Limited

  公开号：US05389626A1

  公开（公告）日：1995-02-14

  Compounds of formula (I): ##STR1## in which: R.sup.1 is hydrogen or acyl; R.sup.2 is hydrogen or C.sub.1 -C.sub.4 alkoxy; and Ar is phenyl or substituted phenyl and pharmaceutically acceptable salts and esters thereof have valuable antibiotic activity, including against Methicillin-resistant strains of Staphylococcus. The invention also provides a process for preparing the compounds and methods and compositions using them.

  公式（I）的化合物：##STR1## 其中：R.sup.1是氢或酰基；R.sup.2是氢或C.sub.1 -C.sub.4烷氧基；Ar是苯基或取代苯基，其药用盐和酯具有有价值的抗生素活性，包括对金黄色葡萄球菌耐甲氧西林菌株的活性。本发明还提供了制备这些化合物的方法以及利用它们的方法和组合物。
• Aminothiazole substituted penicillins and antibacterial compositions
  申请人：Beecham Group P.L.C.

  公开号：US04816452A1

  公开（公告）日：1989-03-28

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof: ##STR1## wherein R.sup.1 is hydrogen or an amino protecting group and R is substituted methyl; optionally substituted C.sub.2-12 alkyl, alkenyl or alkynyl; carbocyclyl; aryl or heterocyclyl. These compounds have antibacterial properties, and therefore are of use in the treatment of bacterial infections in humans and animals caused by a wide range of organisms.

  本发明提供了一种化合物，其化学式为(I)或其药用可接受的盐或体内可水解酯：其中R.sup.1为氢或氨基保护基，R为取代甲基；可选择取代的C.sub.2-12烷基、烯基或炔基；碳环基；芳基或杂环基。这些化合物具有抗菌性能，因此可用于治疗人类和动物因多种微生物引起的细菌感染。
• TACE INHIBITORS
  申请人：——

  公开号：US20030181441A1

  公开（公告）日：2003-09-25

  A compound of the formula 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and Q are as defined above, useful in the treatment of arthritis, cancer, and other diseases involving the dysregulated production/release of reprolysins such as TNF and other diseases characterized by matrix metalloproteinase activity. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID's), COX-2 inhibitors and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

  一种具有以下式1的化合物，其中R1、R2、R3、R4、R5、R6和Q的定义如上所述，在治疗关节炎、癌症和其他涉及重组蛋白酶素（如TNF）异常产生/释放的疾病，以及其他以基质金属蛋白酶酶活性为特征的疾病中有用。此外，本发明的化合物可与标准非甾体类抗炎药（NSAID）、COX-2抑制剂和镇痛药联合治疗，也可与顺铂、多柔比星、顺铂、依托泊苷、紫杉醇、多西他素等细胞毒药物联合使用，用于癌症治疗。